Page 2 - Glenmark Pharmaceuticals Ltd News

Glenmark Pharma falls 5% in 2 days on Q1 show; Here's what analysts suggest

Glenmark Pharma stock has tanked over 5 per cent after the company reported lower-than-expected performance in the June 2025 quarter, missing market estimates

Glenmark Pharma Q1 results: Profit falls 86% to ₹47 cr, revenue down 5%

Gelnmark's India revenue stood at ₹1,239.9 crore, up 3.7 per cent Y-o-Y from ₹1,196.2 crore, driven by growth in cardiac, respiratory, and dermatology segments despite weakness in diabetes portfolio

Glenmark Q1 profit tanks 86% on US settlement hit; revenue stays flat

The sharp profit fall was due to a provision of $37.75 million made by Glenmark to settle US antitrust and consumer protection lawsuit with a putative direct purchaser class, subject to court approval

Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why

Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Stocks to Watch today, July 14: VIP Industries, Adani Green, NCC, DMart

Stocks to Watch today, July 14, 2025: Glenmark Pharma, Avenue Supermarts, RVNL and NCC are some of the top stocks to watch today

Glenmark Pharma soars 10%, hits 52-week high on cancer drug licensing deal

At 09:30 AM, Glenmark Pharma shares were trading at ₹2,094.40, up by 10 per cent on the National Stock Exchange.

Stocks to Watch today, July 11: TCS, IREDA, ZEE, HUL, Tata Steel

Stocks to Watch today, July 11, 2025: TCS, IREDA, Glenmark Pharmaceuticals, HUL and Tata Steel are some of the top stocks to watch today

Glenmark arm inks $700 million licensing deal with US-based AbbVie

IGI Therapeutics, a wholly owned subsidiary of Glenmark, has licensed its cancer and autoimmune drug ISB 2001 to AbbVie for an upfront payment of $700 million

Glenmark Pharma's unit, Abbvie sign global licensing deal for cancer drug

Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize ISB 2001 in North America, Europe, Japan and Greater China

Glenmark hits new high; zooms 37% in 2 months; what's driving pharma stock?

Since June 25, in 12 trading days, the stock has surged 12% after the company launched the lung cancer treatment drug Tevimbra in India, following the approval by the CDSCO.

Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.